日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine

基于肽佐剂的个性化新抗原黑色素瘤疫苗的剂量优化

Valega-Mackenzie, Wencel; Rodriguez Messan, Marisabel; Yogurtcu, Osman N; Nukala, Ujwani; Sauna, Zuben E; Yang, Hong

Dosage optimization for reducing tumor burden using a phenotype-structured population model with a drug-resistance continuum

利用具有耐药性连续谱的表型结构群体模型进行剂量优化,以降低肿瘤负荷。

Han, Lifeng; Yogurtcu, Osman N; Rodriguez Messan, Marisabel; Valega-Mackenzie, Wencel; Nukala, Ujwani; Yang, Hong

A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA's Benefit-Risk Framework

在FDA获益-风险框架下对生物制品评估和研究中心咨询委员会会议进行回顾性审查

Mutanga, Jane Namangolwa; Nukala, Ujwani; Rodriguez Messan, Marisabel; Yogurtcu, Osman N; McCormick, Quinn; Sauna, Zuben E; Whitaker, Barbee I; Forshee, Richard A; Yang, Hong